U.S. biotechnology firm Moderna Inc. is planning to file for the health ministry's approval of its novel coronavirus vaccine as early as Friday, several people familiar with the matter said Tuesday.
The request will be the third such application for regulatory approval in Japan and will be filed with Takeda Pharmaceutical Co., Moderna's partner for its vaccine's clinical study and distribution in Japan.
Takeda recently said it finished the enrollment of study candidates in Japan for Moderna's COVID-19 vaccine in early February, and it is aiming to gain government approval and start distribution in the first half of this year.
Based on an agreement with the government, Takeda will import and distribute 50 million doses of Moderna's vaccine, or enough for 25 million people.
The first batch of 40 million doses is set to be received by the end of June, and a further 10 million doses are scheduled to arrive by the end of September.
Each person would need two shots of the vaccine, spaced 28 days apart.
Japan started administering Pfizer Inc.'s coronavirus vaccine to health workers last month in the first phase of its vaccination program.
Britain's AstraZeneca PLC filed a request for the Health, Labor and Welfare Ministry to approve its COVID-19 vaccine in early February.
Moderna's vaccine uses the same messenger RNA technology as Pfizer's.
Its efficacy rate is 94.1%, according to a U.S. study with 30,000 participants, and is already being administered in the United States and in Europe.
Anaphylaxis from the vaccine is extremely rare, with 1 in 400,000 recipients getting a severe allergic reaction, according to a study from the U.S. Centers for Disease Control and Prevention.
While Pfizer's vaccine needs to be kept at a temperature of around minus 75 degrees Celsius for long-term storage, Moderna's product can be stored for some six months at minus 20 C.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.